⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTMX News
CytomX Therapeutics, Inc.
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
CTMX
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
globenewswire.com
CTMX
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
globenewswire.com
CTMX
Form 8-K
sec.gov
CTMX
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
globenewswire.com
CTMX
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
globenewswire.com
CTMX
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
globenewswire.com
CTMX
CytomX Therapeutics to Present at Upcoming February Conferences
globenewswire.com
CTMX
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
globenewswire.com
CRDF
CTMX
Wareham Development Leases Full Floor at EmeryStation Research Campus to CytomX Therapeutics
businesswire.com
CTMX